**Core Concept**
The question tests the understanding of pharmacological management in **Hypertrophic Obstructive Cardiomyopathy (HOCM)**, focusing on drugs that can worsen the condition. HOCM is characterized by thickening of the heart muscle that can obstruct blood flow.

**Why the Correct Answer is Right**
Although the specific correct answer isn't provided, typically, drugs that increase contractility or reduce ventricular volume are contraindicated in HOCM because they can exacerbate the obstruction. For example, **positive inotropes** like digoxin can increase the contractility of the heart, potentially worsening the obstruction.

**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific options, it's challenging to provide detailed explanations, but generally, any option that does not increase contractility or reduce ventricular volume prematurely would be incorrect.
**Option B:** Similarly, without specifics, we can say that if an option does not typically worsen HOCM symptoms, it would be an incorrect choice.
**Option C:** This option would be incorrect if it represents a drug that is not known to exacerbate HOCM.
**Option D:** Assuming this is the correct answer, the explanation would depend on the drug listed, which is not provided.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that **beta-blockers** are often used in the management of HOCM because they can reduce the heart rate and contractility, thus alleviating the obstruction.

**Correct Answer:** D. Nifedipine